Prof Frank Griesinger, medical oncologist at Pius Hospital, Oldenburg, Germany presents real-world data and outcomes in the US and Germany after first-line treatment with osimertinib  in patients with EGFRm advanced NSCLC.

With the educational support of:

You may also be interested in:

A propensity-based analysis of SBRT & VATS for early-stage lung cancer

Immunotherapy in the peri-operative treatment of patients with early-stage NSCLC

Real-world data after first-line osimertinib

Tags:

poster